title: Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.
abstract: Given that atazanavir (ATV) increases bilirubin in an exposure-dependent manner, we tested whether bilirubin levels could be used as a surrogate of virological response to ATV-based regimens in 182 patients. Bilirubin increases of ≥0.7 mg/dl were independently associated with early virological response with an odds ratio of 5.2 (95% confidence interval 2.2-11.9). Total bilirubin, a nonexpensive, simple, and widely available parameter, might be used as a surrogate of virological response to ATV-based regimens, especially in areas with limited resources where HIV-RNA testing is not available.
authors.affiliation: Laboratory of Molecular Biology, Hospital Carlos III, Madrid, Spain.
authors.forename: Judit
authors.initials: J
authors.lastname: Morello
authors.forename: Elena
authors.initials: E
authors.lastname: Alvarez
authors.forename: Lorena
authors.initials: L
authors.lastname: Cuenca
authors.forename: Eugenia
authors.initials: E
authors.lastname: Vispo
authors.forename: Juan
authors.initials: J
authors.lastname: González-Lahoz
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
authors.forename: Sonia
authors.initials: S
authors.lastname: Rodríguez-Nóvoa
mesh_terms: D000328:Adult; D000483:Alleles; D000069446:Atazanavir Sulfate; D001663:Bilirubin / Q000097:blood; D015415:Biomarkers / Q000097:blood; D018791:CD4 Lymphocyte Count; D060085:Coinfection / Q000097:blood / Q000188:drug therapy / Q000821:virology; D005260:Female; D005500:Follow-Up Studies; D014453:Glucuronosyltransferase / Q000235:genetics; D006678:HIV / Q000472:pathogenicity; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006526:Hepatitis C / Q000097:blood / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood*; D012372:ROC Curve; D012044:Regression Analysis; D012189:Retrospective Studies; D019562:Viral Load; D000099148:UGT1A1 Enzyme
chemical_list: D000069446:Atazanavir Sulfate; D001663:Bilirubin; D015415:Biomarkers; D014453:Glucuronosyltransferase; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D012367:RNA, Viral; D000099148:UGT1A1 Enzyme